We have recently got a lot of questions regarding the newest member of hepatitis c treatment family, Epclusa, and how it compares with previous Hep C treatments. Today we will go over the revolution of new hepatitis c treatments in recent years and review the current treatment options for hepatitis c.
Ribavirin – Nasty!
Not too long ago, before the development of direct acting anti-virals (DDAs), people with chronic hepatitis c had to bet their luck on taking ribavirin coupled with interferon injections. Both drugs caused significant side-effects that are often harmful and dangerous. Even for those who were able to tolerate the treatment, the cure rate was less than 50%.
Sofosbuvir – the new age of DDAs
When the US FDA first approved Gilead’s Sovaldi (sofosbuvir) in December 2013, it was a truely historic milestone in the treatment of hepatitis c. Sofosbuvir was the first DDA that provided a “cure” for chronic hepatitis c patients. With very mild side-effects and only taking one pill a day for 12 weeks, people could improve their chance of curing hepatitis c to nearly 90%.
NS5B + NS5A combination – Today’s gold standard
All you need to know here is that sofosbuvir is the NS5B inhibitor, which remains to be the mainstay in today’s hepatitis c treatment. Shortly after its launch in 2013, research discovered the combination of sofosbuvir with a NS5A inhibitor can prevent treatment resistance and improve the cure rate of hepatitis c to 95% and nearly 100% in some cases. In 2014, Daklinza (daclatasvir), a NS5A inhibitor, was approved in Europe to be used in combination with sofosbuvir. The same year in the USA, Gilead came up with their own NS5B + NS5A combo in a single pill brand named Harvoni (sofosbuvir 400mg + ledipasvir 90mg). The newest member of Gilead’s hepatitis c treatment, Epclusa, is still a NS5B + NS5A combo (sofosbuvir 400mg + velpatasvir 100mg) with ledipasvir been substituted by the new NS5A inhibitor velpatasvir.
Epclusa – the first pan-genomic HCV treatment
There are 6 major sub-types or genotypes of the hepatitis c virus (HCV) 1, 2, 3, 4, 5 and 6.
- The combination of sofosbuvir + daclatasvir has only been shown to effectively treat types 1,2,3,4.
- The combination of sofosbuvir + ledipasvir (Harvoni) has only been shown to effectively treat types 1,4,5,6.
- The combination of sofosbuvir + velpatasvir (Epclusa) can effective treat and has also been approved by the FDA to treat all 6 genotypes!
Before Epclusa, everyone needs to take an HCV genotype test to find out their genotype first before the appropriate treatment option can be determined. This is no longer required today if you intend to take Epclusa for your HCV as it is approved for all 6 genotypes.
For people with type 2 and type 3 HCVs, this also means they now have the option of taking only one pill once a day with Epclusa versus taking 2 pills once a day with the combination of sofosbuvir + daclatasvir, though the cure rates are similar between the two therapies and side-effects for both are similarly mild and tolerable.
Results from advanced clinical trails have shown Epclusa used in combination with ribavirin provides slightly better cure rates in people with advanced decompensated cirrhosis (severe hardening/fibrosis of the liver), Child-Pugh class B or C, compared to combinations containing Harvoni or Daclatasvir.
You can find more information on hepatitis C treatments on our website. We also provide both brand and the most reliable generic HCV medications at the lowest prices. The generic HCV medications we provide are all manufactured by Mylan, a trusted American global leading generic drug company and the 4th largest generic drug company in the world who has been licensed by Gilead to manufacture generic equivalents of Solvaldi, Harvoni, and Epclusa to increase access to HCV treatments in developing countries.
For more information on how you can buy Epclusa (sofosbuvir + velpatasvir), Harvoni (sofosbuvir + ledipasvir), Sovaldi (sofosbuvir), and Daklinza (daclatasvir), please do not hesitate to call us at our toll-free number at 1-888-488-9965 to speak with our pharmacists.